Your cart is currently empty!
NAMSA Insight Session: Why Should You Advocate for Yourself with the FDA?
View
NAMSA Insight Session: What are the 4 Types of FDA Q-Submissions?
View
NAMSA Insight Session: What Happens When Your Lead Reviewer or Team Changes?
View
NAMSA Insight Session: Pre-Submission Meetings-Should You Talk to the FDA or Not? | Part 2
View
NAMSA Insight Session: Pre-Submission Meetings-Should You Talk to the FDA or Not? | Part 1
View
NAMSA Insight Session: How Do You De-Risk Your Trial to Save Time?
View
NAMSA Insight Session: What are the Stages of Clinical Trials?
View
NAMSA Insight Session: What is the FDA’s Thoughts on Physician Experiential Data?
View
NAMSA Insight Session: What is the FDA’s Appetite for Non-Traditional Trial Design? | Part 2
View
NAMSA Insight Session: What is the FDA’s Appetite for Non-Traditional Trial Design? | Part 1
View
NAMSA Insight Session: What’s the Difference Between a Randomized Study vs. Single Arm Performance Goal?
View
NAMSA Insight Session: Have You Argued Your Statistics with the FDA?
View
NAMSA Insight Session: Are There Tracks Similar to Breakthrough for Fast-Tracking Payments from CMS?
View
NAMSA Insight Session: What is the Average Timeframe to Get CMS Coverage?
View
NAMSA Insight Session: What is the Average Time Delay With Regulatory Authorization?
View
NAMSA Insight Session: What Crieteria Does the FDA Use to Approve an IDE Submission?
View
